Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):337-42. doi: 10.1097/00126334-200404010-00002.


High blood levels of the soluble urokinase receptor (suPAR) strongly predict increased mortality in human immunodeficiency virus-1 (HIV-1)-infected patients. This study investigated the plasma concentration of suPAR in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART). Plasma suPAR decreased after introducing HAART, most pronounced during the first treatment year. The change in plasma suPAR was independent of changes in viral replication and CD4+ cells but it was strongly correlated with plasma levels of the soluble TNF receptor II. Compared with healthy individuals, plasma suPAR and sTN-FrII was increased in untreated patients. After initiating HAART, plasma sTNFrII remained increased whereas plasma suPAR decreased to a level comparable with healthy individuals. The present data indicate that the circulating suPAR level is linked to inflammation in untreated as well as HAART-treated HIV-1-infected patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active*
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Drug Administration Schedule
  • Female
  • HIV Infections / blood*
  • HIV Infections / drug therapy*
  • HIV-1
  • Humans
  • Male
  • Receptors, Cell Surface / blood*
  • Receptors, Tumor Necrosis Factor, Type II / blood
  • Receptors, Urokinase Plasminogen Activator
  • Viral Load


  • PLAUR protein, human
  • Receptors, Cell Surface
  • Receptors, Tumor Necrosis Factor, Type II
  • Receptors, Urokinase Plasminogen Activator